Earlier this month, Folium Biosciences submitted a novel food application to the UK Food Standards Agency (FSA) to validate its hemp-derived 0.0% THC broad spectrum cannabidiol oil (CBD).
Earlier this month, Folium Biosciences (Colorado Springs, CO) submitted a novel food application to the UK Food Standards Agency (FSA) to validate its hemp-derived 0.0% THC broad spectrum cannabidiol (CBD) oil. The application was made on behalf of Folium Biosciences Europe BV and a consortium of the various customers of CBD product customers based in the UK to meet the 2020 FSA requirements which require all CBD products to be in the UK market before March 21st Have a Novel Food Application 2020. CBD food products that do not receive regulatory approval before this deadline will no longer be able to sell their products in the UK.
“Folium has a long track record of supply chain quality, safety, consistency and transparency that has enabled us to gain approvals from ethics committees and regulators around the world – even in countries with strict cannabinoid regulations like Japan, Australia, New Zealand and South America, ”said Vanesa Fernandez, Folium’s Chief Scientific Officer, in a press release. “We are proud to continue to demonstrate global CBD leadership as an active participant in regulatory advances in the UK and look forward to next step through the novel food regulatory process in the EU. It is in the best interests of everyone in the CBD industry and the end customers we serve to make product quality and compliance our top priority. “
The novel food application includes the white label finished products, the end products of the customers and the water-soluble hemp oil powder with a wide range. A new type of food approval would therefore ensure that all Folium customer partners can maintain their market advantage with both white label and customer-specific formulations.